

## Supporting Information

### **Modulating the peripheral large steric hindrance of iridium complex for achieving narrowband emission and pure red OLED with EQE up to 32.0%**

Changjin Ou,<sup>‡a</sup> Yu-Chen Qiu,<sup>‡a</sup> Chenhui Cao,<sup>c</sup> Hui Zhang,<sup>a</sup> Juan Qin,<sup>\*a</sup> Zhen-Long Tu,<sup>\*b</sup> Jian Shi<sup>a</sup> and Zheng-Guang Wu<sup>\*a</sup>

<sup>a</sup>. School of Chemistry and Chemical Engineering, Nantong University, Nantong, Jiangsu, 226019, P. R. China. E-mail: [qinjuan880816@ntu.edu.cn](mailto:qinjuan880816@ntu.edu.cn), [wuzhengguang\\_zy@163.com](mailto:wuzhengguang_zy@163.com)

<sup>b</sup>. Research Centre for Information Technology, Shenzhen Institute of Information Technology, Shenzhen, 518172 P. R. China. E-mail: [tuzhenlong@qq.com](mailto:tuzhenlong@qq.com)

<sup>c</sup>. Anhui Sholon New Material Technology Co., Ltd., Chuzhou, Anhui, 239500, P. R. China.

<sup>‡</sup>Changjin Ou and Yu-Chen Qiu contributed equally to this work.

E-mail: [wuzhengguang\\_zy@163.com](mailto:wuzhengguang_zy@163.com)

## 1. General Descriptions

### 1.1 Materials and measurements

All reagents and chemicals were purchased from commercial sources and used without further purification.  $^1\text{H}$  NMR,  $^{19}\text{F}$  NMR,  $^{13}\text{C}$  NMR spectra were measured on a Bruker AM 400 spectrometer. High resolution mass spectra (HRMS) were measured with a LTQ-Orbitrap XL (ThermoFisher, U. S. A.). Absorption and photoluminescence spectra were measured on a UV-3100 spectrophotometer and a Hitachi F-4600 photoluminescence spectrophotometer, respectively. The decay lifetimes were measured with an Edinburgh Instruments FLS-920 fluorescence spectrometer. The absolute photoluminescence quantum yields ( $\Phi$ ) was measured with HORIBA FL-3 fluorescence spectrometer. Cyclic voltammetry measurements were conducted on a MPI-A multifunctional electrochemical and chemiluminescent system (Xi'an Remex Analytical Instrument Ltd. Co., China) at room temperature, with a polished Pt plate as the working electrode, platinum thread as the counter electrode and Ag-AgNO<sub>3</sub> (0.1 M) in CH<sub>3</sub>CN as the reference electrode, *tetra*-*n*-butylammonium perchlorate (0.1 M) was used as the supporting electrolyte, using Fc<sup>+</sup>/Fc as the internal standard, the scan rate was 0.1 V/s.

### 1.2 Theoretical calculation.

The density functional theory (DFT) and time-dependent DFT (TD-DFT) calculations were carried out with Gaussian 09 software package. The geometries of the ground state (S0) were fully optimized with the B3LYP exchange-correlation functional using the LANL2DZ basis set for iridium atom and the 6-31G\*\* basis set for the other atoms both in vacuum and in CH<sub>2</sub>Cl<sub>2</sub> (C-PCM27 solvent model). Vibrational frequency calculations were performed to validate that they are minima on potential energy surface. On the basis of the optimized S0 molecular structures in solvent, TD-DFT calculation was performed. Solvent effect was also considered by using C-PCM model. Frontier molecular orbitals were visualized using Gauss View, and their quantified compositions in percentage on different parts were given by QMForge.


### 1.3 Fabrication and measurements of OLEDs

Indium-tin-oxide (ITO) coated glass with a sheet resistance of 10  $\Omega/\text{sq}$  was used as the anode substrate. Prior to film deposition, patterned ITO substrates were cleaned with detergent, rinsed in

de-ionized water, dried in an oven, and finally treated with oxygen plasma for 5 minutes at a pressure of 10 Pa to enhance the surface work function of ITO anode (from 4.7 to 5.1 eV). All the organic layers were deposited with the rate of 0.1 nm/s under high vacuum ( $\leq 2 \times 10^{-5}$  Pa). The doped layers were prepared by co-evaporating dopant and host material from two individual sources, and the doping concentrations were modulated by controlling the evaporation rate of dopant. LiF and Al were deposited in another vacuum chamber ( $\leq 8.0 \times 10^{-5}$  Pa) with the rates of 0.01 and 1 nm s<sup>-1</sup>, respectively, without being exposed to the atmosphere. The thicknesses of these deposited layers and the evaporation rate of individual materials were monitored in vacuum with quartz crystal monitors. A shadow mask was used to define the cathode and to make ten emitting dots with the active area of 9 mm<sup>2</sup> (3 mm  $\times$  3 mm) on each substrate. Device performances were measured by using a programmable Keithley source measurement unit (Keithley 2400 and Keithley 2000) with a silicon photodiode. The EL spectra were measured with a calibrated Hitachi F-7000 fluorescence spectrophotometer. Based on the uncorrected EL fluorescence spectra, the Commission Internationale de l'Eclairage (CIE) coordinates were calculated using the test program of Spectrascan PR650 spectrophotometer. The EQE of EL devices were calculated based on the photo energy measured by the photodiode, the EL spectrum, and the current pass through the device.

## 2. Experimental Section

### 2.1 Synthesis routes and procedures for the iridium complexes



### 2.1.1 Synthesis of 3-iodoquinolines

To a solution of aromatic amine (5 mmol, 0.46 g), benzaldehyde (5 mmol, 0.53 g), alkyne (5 mmol, 0.51 g) and CuCl (0.5 mmol, 49 mg) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL), the mixture was stirred at room temperature. After 12 h, halide salt KI (7.5 mmol, 1.25 g) was added and then PhI(OAc)<sub>2</sub> (10 mmol, 3.22 g) is slowly added in three batches and the reaction mixture was stirred for another 12 h at room temperature under air. The crude mixture was purified by flash column chromatography to afford the intermediate 3-iodoquinolines (R=H, CF<sub>3</sub>, *t*Bu) with the yields of 72% (1.47 g), 70% (1.66 g) and 75% (1.74 g), respectively.


### 2.1.2 General procedure for the preparation of main ligands

For **L1**, under argon, to a solution of intermediate 3-iodoquinoline (2.0 mmol, 0.81 g), 4-(trifluoromethyl)phenylboronic acid (2.4 mmol, 0.46 g), Pd(PPh<sub>3</sub>)<sub>4</sub> (5 mol%, 0.12 g) and Na<sub>2</sub>CO<sub>3</sub> (4.0 mmol, 0.42 g) in THF(60 mL)/H<sub>2</sub>O (20 mL), the mixture was stirred at reflux for 18 h. After the reaction was cooled to room temperature, H<sub>2</sub>O (100 mL) and CH<sub>2</sub>Cl<sub>2</sub> (40 mL) was added. Then the organic phase was concentrated and purified by flash chromatography on silica gel to give the desired main ligand **L1** with the yield of 75% (0.64g). Using this method, **L2** and **L3** can also be smoothly synthesized with the yields of 78% (0.77 g) and 70% (0.67 g), respectively.

### 2.1.3 General procedure for the preparation of Ir(III) complexes

A mixture of main ligand **L1** (0.25 mmol, 0.11g) and IrCl<sub>3</sub> (0.1 mmol, 29 mg) in 2-ethoxyethanol and water (16 mL, 3 : 1, v/v) was stirred at 130 °C for 24 h under argon. After cooling, the solid precipitate was filtered to obtain crude cyclometalated Ir(III) chloro-bridged dimer. Then, the slurry of crude chloro-bridged dimer, Na<sub>2</sub>CO<sub>3</sub> (1 mmol, 0.11g) and TMHD (1 mmol, 0.18 g) in 2-ethoxyethanol (20 mL) were reacted at 120 °C for 24 h. The solvent was evaporated at low pressure, and the mixture was poured into water. Next, the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> and then chromatographed to give the iridium complex **Ir-CF<sub>3</sub>** with 52% yield (64 mg). Using this method, **Ir-2CF<sub>3</sub>** and **Ir-*t*BuCF<sub>3</sub>** can also be smoothly synthesized with the yields of 50% (68 mg) and 41% (55 mg), respectively.

## 2.2 Characterization data




### 2,4-diphenyl-3-(4-(trifluoromethyl)phenyl)quinoline

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.27 (d, *J* = 8.3 Hz, 1H), 7.76 (ddd, *J* = 8.3, 6.8, 1.4 Hz, 1H), 7.63 – 7.55 (m, 1H), 7.48 (ddd, *J* = 8.2, 6.8, 1.1 Hz, 1H), 7.37 – 7.19 (m, 10H), 7.11 (dd, *J* = 6.6, 3.0 Hz, 2H), 7.02 (d, *J* = 8.0 Hz, 2H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 158.54 (s), 147.94 (s), 147.57 (s), 142.42 (s), 140.68 (s), 136.40 (s), 131.62 (d, *J* = 16.9 Hz), 130.20 (s), 129.98 – 129.69 (m), 128.93 (s), 128.61 (s), 128.29 (s), 127.99 (d, *J* = 13.8 Hz), 127.69 (s), 126.78 (d, *J* = 18.8 Hz), 126.49 (s), 125.40 (s), 124.31 (q, *J* = 3.8 Hz), 122.69 (s).

**<sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>)** δ -62.51.




**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.41 (dd, *J* = 7.0, 2.8 Hz, 2H), 7.72 (d, *J* = 8.0 Hz, 2H), 7.63 (d, *J* = 8.4 Hz, 2H), 7.52 – 7.45 (m, 6H), 7.43 – 7.40 (m, 2H), 7.36 – 7.32 (m, 6H), 7.28 (d, *J* = 7.4 Hz, 2H), 7.16 (t, *J* = 7.5 Hz, 2H), 6.72 (dd, *J* = 6.2, 1.9 Hz, 2H), 6.66 (d, *J* = 7.6 Hz, 2H), 6.50 – 6.44 (m, 6H), 4.90 (s, 1H), 0.85 (s, 18H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 193.87 (s), 168.65 (s), 153.83 (s), 149.36 (s), 148.28 (s), 147.62 (s), 142.74 (s), 137.29 (s), 136.28 (s), 131.75 (s), 131.47 (s), 130.50 (d, *J* = 13.2 Hz), 129.94 (s), 129.38 (t, *J* = 16.3 Hz), 128.44 (s), 127.96 – 127.44 (m), 126.24 (d, *J* = 14.2 Hz), 125.58 (s), 125.38 (s), 125.05 (s), 119.78 (s), 88.23 (s), 40.96 (s), 28.19 (s).

**<sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>)** δ -62.47.

**HRMS (ESI)** *m/z* calcd for C<sub>67</sub>H<sub>53</sub>F<sub>6</sub>IrN<sub>2</sub>O<sub>2</sub>H [M+H]: 1225.3719, found: 1225.3719.




**4-phenyl-2,3-bis(4-(trifluoromethyl)phenyl)quinoline**

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.26 (d, *J* = 8.4 Hz, 1H), 7.79 (ddd, *J* = 8.3, 6.9, 1.3 Hz, 1H), 7.62 (d, *J* = 8.2 Hz, 1H), 7.54 – 7.44 (m, 5H), 7.31 (dd, *J* = 7.1, 4.0 Hz, 5H), 7.12 (dt, *J* = 4.1, 3.4 Hz, 2H), 7.03 (d, *J* = 8.1 Hz, 2H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 156.87 (s), 148.42 (s), 147.55 (s), 144.26 (s), 141.85 (s), 136.06 (s), 131.64 (s), 131.29 (s), 130.39 – 129.99 (m), 129.80 (s), 129.03 (s), 128.71 (s), 128.14 (s), 127.88 (s), 127.38 (s), 126.71 (d, *J* = 11.4 Hz), 125.40 (s), 125.27 (s), 124.95 – 124.35 (m), 122.63 (d, *J* = 12.6 Hz).


**<sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>)** δ -62.57, -62.64.



**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.25 – 8.12 (m, 2H), 7.60 (q, *J* = 8.4 Hz, 4H), 7.53 (d, *J* = 7.7 Hz, 2H), 7.49 – 7.46 (m, 2H), 7.43 – 7.36 (m, 6H), 7.33 – 7.27 (m, 4H), 7.23 (t, *J* = 7.5 Hz, 2H), 7.10 (t, *J* = 7.5 Hz, 2H), 6.83 (s, 2H), 6.66 (dd, *J* = 8.6, 1.4 Hz, 2H), 6.59 (d, *J* = 7.6 Hz, 2H), 6.46 (d, *J* = 8.5 Hz, 2H), 4.82 (s, 1H), 0.76 (s, 18H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 194.02 (s), 167.25 (s), 152.31 (s), 151.38 (s), 150.22 (s), 148.12 (s), 142.20 (s), 135.90 (s), 133.16 (s), 131.83 (s), 131.31 (s), 131.04 (s), 130.65 (d, *J* = 12.8 Hz), 130.22 – 129.83 (m), 129.40 (d, *J* = 12.8 Hz), 128.47 (s), 127.85 (d, *J* = 12.8 Hz), 127.41 (s), 126.97 (s), 126.59 (s), 125.53 (d, *J* = 12.8 Hz), 117.09 (s), 88.50 (s), 41.01 (s), 28.20 (s).


**HRMS (ESI)** *m/z* calcd for C<sub>67</sub>H<sub>53</sub>F<sub>6</sub>IrN<sub>2</sub>O<sub>2</sub>H [M+H]<sup>+</sup>: 1361.3466, found: 1361.3466.



**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.26 (d, *J* = 8.4 Hz, 1H), 7.79 – 7.70 (m, 1H), 7.58 (d, *J* = 7.9 Hz, 1H), 7.47 (dd, *J* = 11.1, 4.0 Hz, 1H), 7.31 – 7.21 (m, 9H), 7.11 (dd, *J* = 6.5, 2.9 Hz, 2H), 7.03 (d, *J* = 8.0 Hz, 2H), 1.26 (s, 9H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 158.53 (s), 150.96 (s), 147.82 (s), 147.58 (s), 142.56 (s), 137.70 (s), 136.49 (s), 131.63 (d, *J* = 18.8 Hz), 130.21 (s), 129.75 (s), 129.54 (s), 128.52 (s), 128.11 (d, *J* = 17.3 Hz), 127.63 (s), 126.68 (d, *J* = 4.6 Hz), 126.40 (s), 124.89 (s), 124.26 (d, *J* = 3.8 Hz), 34.55 (s), 31.23 (s).

**<sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>)** δ -62.50.





**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.31 (d, *J* = 7.4 Hz, 2H), 7.74 – 7.63 (m, 4H), 7.51 (s, 6H), 7.38 (dd, *J* = 23.0, 6.9 Hz, 8H), 7.18 (d, *J* = 7.1 Hz, 4H), 6.77 – 6.65 (m, 4H), 6.50 (d, *J* = 8.3 Hz, 2H), 6.36 (d, *J* = 8.4 Hz, 2H), 4.91 (s, 1H), 0.87 (s, 36H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 192.73 (s), 166.99 (s), 153.75 (s), 148.50 (s), 147.97 (s), 147.17 (s), 144.19 (s), 141.88 (s), 135.48 (s), 133.46 (s), 130.84 (s), 130.37 (s), 129.55 (s), 129.31 (s), 128.87 (s), 128.30 (d, *J* = 10.8 Hz), 128.00 (s), 127.22 (s), 126.99 (s), 126.49 (s), 125.10 (s), 124.55 (d, *J* = 10.8 Hz), 116.18 (s), 87.10 (s), 39.86 (s), 32.93 (s), 29.88 (s), 27.22 (s).



**<sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>)** δ -62.37.



**HRMS (ESI)** *m/z* calcd for C<sub>67</sub>H<sub>53</sub>F<sub>6</sub>IrN<sub>2</sub>O<sub>2</sub>H [M+H]: 1337.4971, found: 1337.4970.



## 2.3 NMR Spectra




























## 2.4 HR Mass Spectra

### Acquisition Parameter

Source Type ESI  
Focus Active  
Scan Begin 50 m/z  
Scan End 1500 m/z

Ion Polarity Positive  
Set Capillary 4500 V  
Set End Plate Offset -500 V  
Set Collision Cell RF 1040.0 Vpp

Set Nebulizer 0.4 Bar  
Set Dry Heater 180 °C  
Set Dry Gas 4.0 l/min  
Set Divert Valve Waste




### Acquisition Parameter

Source Type ESI  
Focus Active  
Scan Begin 50 m/z  
Scan End 1500 m/z


Ion Polarity Positive  
Set Capillary 4500 V  
Set End Plate Offset -500 V  
Set Collision Cell RF 1040.0 Vpp

Set Nebulizer 0.4 Bar  
Set Dry Heater 180 °C  
Set Dry Gas 4.0 l/min  
Set Divert Valve Waste




**Acquisition Parameter**

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Active	Set Capillary	4500 V	Set Dry Heater	180 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	1500 m/z	Set Collision Cell RF	640.0 Vpp	Set Divert Valve	Waste


**3. Supplementary data**

**Table S1** HOMO and LUMO electron cloud density distribution of each fragment of the Ir(III) complexes


Complex	Orbital	Energy/eV (Experiment)	Energy/eV (Calculated)	Composition (%)		
				Main Ligand	Ir	Ancillary Ligand
<b>Ir-CF<sub>3</sub></b>	HOMO	-5.19	-5.18	60.34	35.75	3.91
	LUMO	-2.89	-1.93	94.16	4.44	1.40
<b>Ir-2CF<sub>3</sub></b>	HOMO	-5.45	-5.51	42.14	36.11	21.75
	LUMO	-3.09	-2.22	94.06	4.42	1.52
<b>Ir-<i>t</i>BuCF<sub>3</sub></b>	HOMO	-5.11	-5.05	46.06	25.48	28.46
	LUMO	-2.85	-2.10	96.93	2.08	0.99




**Fig. S1** Thermogravimetric analysis (TGA) of **Ir-CF<sub>3</sub>**, **Ir-2CF<sub>3</sub>** and **Ir-*t*BuCF<sub>3</sub>**.




PLQY of **Ir-CF<sub>3</sub>** in CH<sub>2</sub>Cl<sub>2</sub>




PLQY of **Ir-2CF<sub>3</sub>** in CH<sub>2</sub>Cl<sub>2</sub>




PLQY of **Ir-BuCF<sub>3</sub>** in CH<sub>2</sub>Cl<sub>2</sub>



PLQY of **Ir-CF<sub>3</sub>** in doped film of 5 wt% in the 26DCzPPy




### PLQY of Ir-2CF<sub>3</sub> in doped film of 5 wt% in the 26DCzPPy





### PLQY of Ir-BuCF<sub>3</sub> in doped film of 5 wt% in the 26DCzPPy

**Fig. S2** The photoluminescence quantum yields (PLQYs) of Ir-CF<sub>3</sub>, Ir-2CF<sub>3</sub> and Ir-BuCF<sub>3</sub>.




**Fig. S3** The lifetime curves of  $\text{Ir-CF}_3$ ,  $\text{Ir-2CF}_3$  and  $\text{Ir-tBuCF}_3$ .






**Fig. S4.** EL performances in different doping concentrations: (a) EL spectra; (b), (c) and (d) current efficiency versus luminance curves.

**Previous work:**



**This work: EQE<sub>max</sub> > 28%**



**Fig. S5** The devices performances of 2-phenylquinoline ligand-based Ir(III) complexes.